key: cord-0916478-gvea4bsp
authors: Wu, Tong; Rabi, Seyed A.; Michaud, William A.; Becerra, David; Gilpin, Sarah E.; Mino-Kenudson, Mari; Ott, Harald C.
title: Protease inhibitor Camostat Mesyalte blocks wild type SARS-CoV-2 and D614G viral entry in human engineered miniature lungs
date: 2022-04-11
journal: Biomaterials
DOI: 10.1016/j.biomaterials.2022.121509
sha: 2a7e33bf3e270c63f0e70d8adb9e1ee38201cd81
doc_id: 916478
cord_uid: gvea4bsp

The catastrophic global effects of the SARS-CoV-2 pandemic highlight the need to develop novel therapeutics strategies to prevent and treat viral infections of the respiratory tract. To enable this work, we need scalable, affordable, and physiologically relevant models of the human lung, the primary organ involved in the pathogenesis of COVID-19. To date, most COVID-19 in vitro models rely on platforms such as cell lines and organoids. While 2D and 3D models have provided important insights, human distal lung models that can model epithelial viral uptake have yet to be established. We hypothesized that by leveraging techniques of whole organ engineering and directed differentiation of induced pluripotent stem cells (iPSC) we could model human distal lung epithelium, examine viral infection at the tissue level in real time, and establish a platform for COVID-19 related research ex vivo. In the present study, we used type 2 alveolar epithelial cells (AT2) derived from human iPSCs to repopulate whole rat lung acellular scaffolds and maintained them in extended biomimetic organ culture for 30 days to induce the maturation of distal lung epithelium. We observed emergence of a mixed type 1 and type 2 alveolar epithelial phenotype during tissue formation. When exposing our system to a pseudotyped lentivirus containing the spike of wildtype SARS-CoV-2 and the more virulent D614G, we observed progression of the infection in real time. We then found that the protease inhibitor Camostat Mesyalte significantly reduced viral transfection in distal lung epithelium. In summary, our data show that a mature human distal lung epithelium can serve as a novel moderate throughput research platform to examine viral infection and to evaluate novel therapeutics ex vivo.

Corresponding author: 20 21

Harald C Ott, MD 22

Associate Professor of Surgery Introduction 1 SARS-CoV-2, the coronavirus that causes COVID-19, has claimed the lives of 5.9 million people worldwide 2 while infecting more than 400 million patients. The necessary development time of vaccines and the 3 emergence of SARS-CoV-2 variants highlight the significant lag and limited adaptability of the vaccine 4 approach and the need for novel therapeutics. Among all causes of mortality, acute respiratory failure 5 (ARF) with diffuse alveolar damage was found in most patients(1, 2). To investigate how to intervene in 6 this disease process and to inhibit various steps of the SARS-CoV-2 lifecycle, we need a universally 7 available, affordable, scalable, and yet physiologically relevant platform simulating the human respiratory 8 tract. Recently, several groups reported the application of human lung cells(3, 4), organoids(5-8), and 9

organ-on-a-chip microfluidic systems(9-13) for the study of SARS-CoV-2 infection and induced immune 10 responses. However, the discrepancies between these platforms and native human lung make it hard to 11 recapitulate the pathophysiological behavior of SARS-CoV-2 virus during infection. SARS-CoV-2 employs 12

Angiotensin-converting Enzyme-2 (ACE2) as a receptor for cellular entry(3), the expression of which is 13 abundantly distributed throughout the human lung epithelium(14), including alveolar type 1 (AT1) and 14 2 (AT2) cells and small airway epithelial cells(15). In native lungs, AT1 cells are essential for gas exchange 15 and barrier formation, while AT2 cells secrete surfactant to support fluid balance and also function as the 16 progenitor population for AT1 cells to maintain tissue homeostasis (16) . Autopsies have shown that both 17 cell types are depleted in the context of SARS-CoV-2 infection, and that there is evidence of trans-18 differentiation and attempted epithelial repair between those cell types(17). Human lung epithelial cells 19 that exhibit AT2 cell identity can be generated from iPSCs and expand as alveolar epithelial spheres in 20 J o u r n a l P r e -p r o o f mature distal lung epithelium and provide a physiologically relevant model for the study of the SARS-1

CoV-2 viral pathobiology and the evaluation of therapeutic interventions. immunofluorescent staining (Fig.1a) , indicating that AECs generated from human iPSCs indeed exhibited 9

features of AT2 cell identity in vitro. In preparation for cell seeding, acellular rat lungs were cannulated 10 via trachea and pulmonary artery (PA), enabling cell seeding via airway and constant media perfusion via 11 the pulmonary vasculature (Fig.1b&c) . Rat lungs were each seeded with 20 million AECs and were 12 maintained in extended organ culture for 30 days (Fig.1d&e ). One lobe of each regenerated lung was 13 removed every 6 days for analysis (Supplementary Table 1 ). We observed increasing epithelial coverage 14 over the culture duration, suggesting continuous proliferation of AECs on scaffolds (Fig.1f, Supplementary  15   Fig.1a ). Histologic analysis of the engineered lung at later stages of culture, such as 24 and 30 days, 16 revealed an increasingly organized distal lung epithelium (Fig.1f ). To better understand the level of 17 maturity and to match engineered lungs with human developmental stages, we obtained fetal and 18 neonatal human lungs from pseudoglandular, canalicular and saccular stages. We observed comparable 19 morphology of engineered lungs at culture day 30 to late canalicular to early saccular stage human lung 20 tissue (Fig.1g) , showing the formation of distal airway and the completion of branching 1 morphogenesis(20, 21). Histologic analysis of fetal/neonatal rat lung supported a similar conclusion 2 ( Supplementary Fig.1b) . We then calculated the average area and number of alveoli in fetal/neonatal 3 human lungs and engineered lung at 30 days of extended organ culture. Via morphometric analysis, we 4 observed that alveolar size in engineered lungs gradually increased over the culture duration, ultimately 5 reaching metrics comparable to fetal/neonatal human lung at late canalicular to early saccular stages 6 ( Fig.1 h&i) . Immunofluorescent staining of engineered lungs showed the persistent expression of Nkx2.1, 7 CDH1, ProSPC, and SPB throughout organ culture (Fig.2a&b ). Compared to in vitro cultured AECs, 8 engineered lung tissue showed a higher expression of CDH1 throughout the culture duration, and initially 9 equivalent levels of Nkx2.1, which decreased towards to end of culture (Fig.2c) . The expression of ProSPC 10 was slightly lower in engineered tissue, while SPB was comparable to AECs. As a point of reference, we 11 analyzed expression of Nkx2.1, CDH1, ProSPC, and SPB in fetal/neonatal lungs at different developmental 12 stages (Fig.2d&e) . The observed gene expression pattern of developing alveoli further indicated that 13 regenerated lungs resemble canalicular stage human lungs to certain extent. 14 15

After an initial engraftment period, we observed stable AEC proliferation over the culture duration with 17 an increase of Ki67 expression from day 6 to day 18 and 24, and a slight decrease at day 30 ( Fig.3a,b) . 18

QRT-PCR confirmed that the expression levels of Ki67 were lower at day 6 and day 30, the beginning and 19 end of organ culture, than day 12, 18, and 24 (Fig.3c) . TUNEL staining of lung samples showed 20 consistently low number of apoptotic cells (<10%) throughout the culture duration (Supplementary 1 Fig.1c) . These results demonstrated the compatibility of acellular scaffolds and AECs, and a stable cellular 2 proliferation of AECs after engraftment. Corresponding to cell proliferation, we observed a steady 3 increase of epithelial coverage over the culture duration, which ultimately reached 82.04%±8.89% at day 4 30 (Fig.3d ). To correlate morphologic data with viable cell quantification, we performed a Resazurin 5 based metabolic assay before each biopsy(22). At 6 days after seeding of 20M cells, 32.88±7.61M viable 6 cells were found in engineered lungs, and the number reached 99.89±3.14M by the end of 30 days 7 extended organ culture (Fig.3e) . Glucose consumption and lactate production in culture medium both 8 confirmed the continuous proliferation of metabolically active AECs in EMLs (Fig.3f&g) . The levels of pH, 9 pO2, and pCO2 remained within healthy limits, but showed a slight trend towards under-perfusion 10 towards the end of culture ( Supplementary Fig.1e) . to squamous over the course of the culture duration (Fig.4a) . This may indicate that trans-differentiation 18 of AT2 cells towards an AT1 fate may have occurred. We further observed the expression of human AT2 19 cell marker protein HTII-280 in a minority of cells at later organ culture days with an average of 1 0.030%±0.012% (Fig.4b) . A similar shift in number and phenotype of AQP5, and HTII-280 positive cells 2 was observed in fetal and neonatal human lungs further supporting the engineered lung's resemblance 3 to canalicular to saccular stage human lungs ( Fig.4c and Supplementary Fig.2a&b ). 3D reconstructions of 4 tissue after 30 days of culture show that engineered epithelium consisted of well-organized, intact alveoli 5 with broad expression of SPB, and luminal expression of AQP5 suggesting a mixed AT1 and AT2 6 phenotyped epithelium in EMLs (Fig.4d) . 7

To quantify cell fate conversion during tissue formation, we recorded the number of cells that were 8 expressing only AQP5, SPB, or co-expressing both markers in engineered miniature lungs over time. As 9 shown in Figure 4e , the ratio of AQP5 expressing cells increased from day 6 to day 24, while the ratio of 10 SPB expressing cells and double positive (DP) cells remained stable during culture. Measurement of 11 fluorescence intensity showed that while epithelial coverage rate increased constantly during culture, 12 the fluorescent area of SPB and AQP5 had also increased (Fig.4f) . The mean fluorescent intensity of SPB 13 decreased slightly during culture, while AQP5 remained stable ( Supplementary Fig.1g ). We correlated 14 fluorescent area with mean fluorescent intensity to calculate the integrated density, which showed 15 increase of both SPB and AQP5 in engineered tissue during organ culture (Fig.4f,g) . QRT-PCR results 16 further suggested the appearance of AT1 phenotyped cells upon extended organ culture by showing that 17 several AT1 markers, including AQP5, Podoplanin (PDPN), and HOPX, all significantly increased during 18 organ culture (Fig.4e) . 19 J o u r n a l P r e -p r o o f 1

To test the validity of engineered miniature lungs as a discovery tool in COVID-19 related research, we 3 studied the viral entry of SARS-CoV-2 in 3D culture and its inhibition with protease inhibitiors. SARS-CoV-4 2 viral entry into lung epithelial cells depends on the cell surface receptor angiotensin-converting 5 enzyme 2 (ACE2)(3). As a first step, we confirmed ACE2 expression in BU3-NGST alveolar spheres and 6 engineered lung at day 30 of extended organ culture ( Supplementary Fig. 3a) . We then generated a Spike 7 protein pseudotyped GFP-expressing lentivirus to mimic the viral entry process. To avoid the conflict of 8

Nkx2.1-GFP marker protein expression with GFP expressing pseudotyped virus, we derived a second AEC 9 line from human iPSC SPC2 for the following experiments. SPC2 alveolar spheres showed comparable 10 gene expression levels of ACE2 and TMPRSS2, a protease essential for Spike protein priming, and showed 11 expression of AT2 cell marker genes ( Supplementary Fig.2b&c ). We therefore proceeded to seed whole 12 rat lung scaffolds with SPC2 AECs as described and cultured the resulting constructs for 26 days at which 13 point viral infection was induced via tracheal instillation (Fig.5a&b) . H&E staining showed epithelial tissue 14 morphology before and after virus infection as described above ( Supplementary Fig.2d) . 15

Immunofluorescent staining of GFP and ACE2 in regenerated lung showed that the majority of GFP and 16 ACE2 expression was co-localized, while GFP signals could be observed in live cultured lungs (Fig.5c&d) . 17

A concerning feature of SARS-CoV-2 is its ability to mutate. These viral variants could pose a challenge 18 towards development of effective therapeutic agents. An early amino acid change in the Spike protein of 19 some strains of SARS-CoV-2 was identified early in the pandemic. This variant, labeled D614G has become 20 the dominant form globally since March 31, 2020. In vitro experiments have shown that this mutation 1 confers an evolutionary advantage to the virus by increasing viral entry(25, 26). In our model of 2 engineered miniature lungs, we studied if the D614G mutation alters the entry efficiency of the SARS-3

CoV-2(25, 26), and if the infection could be blocked by known protease inhibitors(3, 4). We cultured EMLs 4 for 24 hours with or without 50uM Camostat Mesyalte at a concentration found to be effective on 2D 5 cultured AECs ( Supplementary Fig.3a , b, d). We then infected EMLs with either wildtype (WT) or D614G 6 viruses while keeping Camostat Mesyalte in culture medium (Fig.5e ). Immunostaining showed that 7 although the expression of cellular receptor ACE2 remained the same across EMLs, pre-treatment with 8

Camostat Mesyalte significantly blocked the viral entry in both WT and D614G virus-infected lungs (Fig.5f) . 9

As expected, non-treated D614G virus infected lung overall showed more GFP+ cells than non-treated 10 Immunostaining showed that GFP signal could be detected in both AQP5 expressing, and SPB expressing 19 epithelial cells, indicating that AECs exhibiting AT1, AT2, or intermediate phenotypes were susceptible to 20 infection by both pseudotyped viruses, either WT or D614G (Fig.5h, Supplementary Fig.4a ). We 1 quantified the ratio of GFP expression in AQP+, SPB+, DP, and all cells, the result showed no significant 2 differences of viral infection efficiency between different cell populations (Fig. 5i) . In all engineered lungs 3 infected by either WT or D614G, with or without Camostat Mesyalte, we observed ACE2 expression 4 among all cell populations as well, indicating the SARS-CoV-2 pseudotyped viral infection was mediated 5 by ACE2 in AECs with AT1 phenotype as well as AT2 phenotype (Supplementary Fig.4b) . The worldwide COVID-19 pandemic has cost nearly 6 million lives and continues to challenge health care 9 systems and humanity across the globe. While various vaccines have shown drastic effects on preventing 10 COVID-19 infection and reducing its severity, the discovery of effective novel forms of treatment of 11 COVID-19 has lagged behind. To study this devastating disease and its pathophysiology, in vitro models 12 mimicking human lung tissue including 3D cultured organoids(5-8), air-liquid interface cultured 13 epithelium(11, 27-29), and lung-on-a-chip(9-13) have provided valuable research platforms. However, 14 none of these replicate the structure of human lungs, therefore limiting the ability to simulate and 15 analyze critical events during and after COVID-19 infection, including the primary infection, disease 16 progression and the related pathophysiology of airway cells(30). We have learned that the Spike protein 17 of SARS-CoV-2 mediates binding to ACE2 to enter target cells. ACE2 is an important regulator in the 18 renin-angiotensin-system (RAS) and plays crucial role in SARS-CoV induced lung injury(31, 32). Similarly, 19

SARS-CoV-19 uses ACE2 as a receptor for cellular entry(33, 34), the expression of which had been found 20 in lung AT2 cells(35). Autopsy samples showed that diffuse alveolar damage was found in many severe 1 COVID-19 patients, while pulmonary alveolar regeneration led by AT2 cells was observed in some 2 survivors(1, 2, 36). Currently available 2D and 3D models built on primary or iPSC derived cells have 3 not reached functional maturity of a mixed AT1/AT2 cell epithelium and therefore cannot simulate 4 epithelial infection, damage, and repair. 5

Over the past decade, several groups have developed and refined organ engineering techniques based 6 on perfusion decellularized lung scaffolds (37). While engraftment of epithelial cells has been described, 7

to date no mature epithelial phenotype and morphology has been detected in engineered tissue 8 constructs(38, 39). Recently, improved differentiation efficiency of lung epithelial cells derived from 9 human iPSCs has been described, yet extensive distal lung tissue formation and surfactant secretion has 10 yet to be obtained(40). 11

In the present study we aimed to show that iPSC derived AECs can be engrafted on rat lung scaffolds to 12 form engineered miniature lungs. When cultured over extended time, iPSC derived AECs mature formed 13 a stage corresponding to the pseudoglandular stage(41) featuring an epithelium corresponding to late 14 canalicular to early saccular stage with a gradually increasing number of AQ5 expressing AT1 phenotyped 15 cells and HTII-280 expressing AT2 cells. Aquaporin 5 expression identifies AT1 cell fate(42), yet additional 16 work is required to fully understand this emerging cell type during tissue formation in EMLs. To date, no 17 in vitro differentiation protocol for the generation of AT1 cells from human iPSCs has been reported. Our 18 results indicate that the process of tissue formation on acellular scaffolds may contribute signals that 19 drive cell fate conversion from an AT2 to an AT1 phenotype. HTII-280 had been found to be a human AT2 20 J o u r n a l P r e -p r o o f cells specific surface marker protein(43), and had been widely used for purification of primary AT2 cells 1 from donor human lungs (19, 44, 45) . It is developmentally regulated, and the expression level increases 2 with gestation weeks(43). The expression of HTII-280 has not been described in human iPSC derived 3 alveolar spheres (18, 19, 46) . Our data further showed the expression of ACE2 in a large number of 4 isolated AECs, and confirmed that Spike protein mediated viral entry is ACE2 dependent in both 5 isolated AECs and EMLs. 

The psPAX2 plasmid was a gift from Didier Trono (Addgene plasmid # 12260 ; 10 http://n2t.net/addgene:12260 ; RRID:Addgene_12260) and is a lentiviral packaging vector. The pSin-GFP-11 IRES-Puro vector was made using pSin-EF-Sox2-Puro, which was a gift from James Thomson (Addgene 12 plasmid # 16577 ; http://n2t.net/addgene:16577 ; RRID:Addgene_16577). The gfp ORFs was subcloned 13 into the pSin-EPB-IRES-Puro using the EcoRI and BamHI sites. Bio). Three days later, the supernatant was collected and spun at 350xg for 10 minutes at 4 o C, then 8 filtered through a 0.45 µM filter. The virus was then pelleted by ultracentrifugation at 100,000 x g over a 9

20% sucrose cushion. The virus was then quantified using the Lenti-X™ p24 Rapid Titer Kit (Takara Bio) 10 and aliquots were frozen at -80 o C for future use. 11 12

The differentiation of iPSCs was performed following previously published protocols with modifications 14 (18, 19, 41, 52, 53) . Briefly, BU3-NGST iPSC that carries two fluorescent reporters, Nkx2.1 GFP and 15 SPC tdTomato , and SPC2 iPSC that carries fluorescent reporters SPC tdTomato were maintained in mTeSR 

Cadaveric rat lungs were decellularized as previously described (37, 54, 55) . Rat lungs were explanted 18 from male Sprague-Dawley rats (250-300 g, Charles River Laboratories) and pulmonary artery (PA) of 19 each lung was cannulated. Lungs were then perfused by 0.1% sodium dodecyl sulfate (SDS) solution 20 through PA for 2 hours, followed by 15 minutes of deionized water, 10 minutes of 1% Triton X-100, and 1 extensive PBS washing in decellularization chamber. Rat lungs were mounted in bioreactors prefilled with 100 mL alveolar sphere expansion medium then 5 perfused for 1 hour by PA at 1 mL/min, in a 37°C, 5% CO2 incubator, where the remainder of culture were 6 carried out. Alveolar spheres were trypsinized into single cells and 20 million alveolar epithelial cells re-7 suspended in 50mL medium obtained from the bioreactors were seeded into each lung and delivered via 8 airways by gravity at a height of 30 cm. 9

After seeding, the bioreactors were returned to incubator and given a 1.5-2 hour static culture time for 10 cell attachment. PA perfusion was then reinitiated at 4 mL/min and carried on through the culture. 11

Culture medium was changed every 3 days with increased volume every 2 changes, while one lobe was 12 removed for biopsy every 6 days (Fig.1f, Supplementary Table 1 ). RNA samples were stored in Trizol (Life 13

Technologies) and rest of the lung was fixed with 4% Paraformaldehyde (PFA) overnight. On day 30, left 14 lung was perfusion fixed through the trachea overnight. 15 16

Alveolar spheres were trypsinized to generate single cells then seeded on 1% Matrigel coated 48 well 18 tissue culture plates for infection. Attached cells were incubated with 100ul of virus containing medium 19 for 1 day then changed back with alveolar cell medium. For small molecule test, medium containing 20 20μM or 50μM Camostat Mesylate (SigmaAldrich) or E64-D (SigmaAldrich), and 2 μM or 10 μM 1 Ampilimod (MedChemexpress) was added to cells 1 day before infection, and was kept in the medium 2 during infection. Engineered lungs cultured for 26 days were transferred from original incubator for 3 extended organ culture to a new small incubator which runs with a minimum of 25ml medium (Fig. 5b) . 4

Medium containing WT or D614G pseudotyped viruses were added into the incubator and perfused at 5 1ml/min for 24 hours before transferring back to the normal organ culture incubators. For small molecule 6 inhibition assay on the regenerated lung, medium containing 50μM Camostat Mesylate was used for lung 7 perfusion starting from Day 25, 24 hours before virus infection. Supplementary Fig.1d) . Technologies). Gene expression was quantified by Taqman assay (Life Technologies) using the One Step 4

Plus system (Applied Biosystems). Gene expression was analyzed by normalizing to housekeeping gene 5 beta-actin, and presented relative to in vitro cultured alveolar spheres. 6 7

Regenerated lungs were digested following a previously published protocols with modifications(56). 9

Briefly, regenerated lungs were cut into small pieces on ice and about 300mg tissue was placed in C tubes 10 to the reduction of total lung volume caused by lobe removal, which was measured by average weight 10 of cadaveric rat lungs (Supplementary Fig 2) . To correct for this, cell numbers estimated by Resazurin 1 assay were normalized to the remaining volume of EMLs at the time each essay was conducted 2 (Supplementary Table 1 Table 2 ), glucose consumption and lactate production still plateaued during later time 6 points ( Fig.3f&g) , implying the need for more medium and/or more frequent medium change. The ratio of AQP5 expressing cells increased significantly from day 6 to day 24. g. Calculation of integrated 7 densities of SPB and AQP5 of immunofluorescent images of EMLs at different organ culture days. h. 8

Quantitative RT-PCR gene expression analysis of AQP5, AGER, and PDPN in EMLs at different organ culture 9 days. Gene expression levels were normalized to the housekeeping gene beta-actin, and presented 10 relative to in vitro cultured AECs. We designed a small sized organ culture bioreactor system that allowed us to use as few as 25ml of virus 5 containing medium for the system. c. Immunofluorescent images show the expression of ACE2 and GFP 13  14  15  16  17  18  19  20  21  22  23  24  25  26  27 

Analysis of the clinical characteristics of 77 COVID-19 deaths

Alveolar epithelial cells: master regulators of lung homeostasis. The international 1 journal of biochemistry & cell biology

A single-cell and spatial atlas of autopsy tissues reveals pathology and cellular 3 targets of SARS-CoV-2. bioRxiv

Efficient Derivation of Functional Human Airway Epithelium from 5

Pluripotent Stem Cells via Temporal Regulation of Wnt Signaling

Differentiation of Human Pluripotent Stem Cells into Functional Lung Alveolar 8 Epithelial Cells

Influence of air pollution on respiratory health during perinatal 10 development

Building and maintaining the epithelium of the lung

Ex vivo non-invasive assessment of cell viability and proliferation in bio-engineered 14 whole organ constructs

Early lineage specification defines alveolar epithelial ontogeny in the murine 16 lung

Reconstructing lineage hierarchies of the distal lung epithelium using single-18 cell RNA-seq

SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission 20 in vivo

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity 22 of the COVID-19 Virus

SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling 24 and drug discovery. bioRxiv

A robust SARS-CoV-2 replication model in primary human epithelial cells at the 26 air liquid interface to assess antiviral agents

Resveratrol and Pterostilbene Inhibit SARS-CoV-2 Replication in Air-Liquid 28 Interface Cultured Human Primary Bronchial Epithelial Cells

Novel and Evolving Therapies for COVID-19 Related Pulmonary 30 Complications()

Angiotensin-I-converting enzyme and its relatives

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-33 induced lung injury

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune 35 cross-reactivity with SARS-CoV

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Single-cell RNA expression profiling of 39

ACE2, the receptor of SARS-CoV-2. BioRxiv

Pulmonary alveolar regeneration in adult COVID-19 patients. Cell 2 Res 30

Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial 4 heart

Bioengineered lungs generated from human iPSCs-derived epithelial cells on 6 native extracellular matrix

Enhanced lung epithelial specification of human induced pluripotent stem cells 8 on decellularized lung matrix

Human iPS cell-derived alveolar epithelium repopulates lung extracellular matrix

Prospective isolation of NKX2-1-expressing human lung progenitors derived 12 from pluripotent stem cells

Keratinocyte growth factor modulates alveolar epithelial cell phenotype in vitro: 14 expression of aquaporin 5

HTII-280, a biomarker specific to the 16 apical plasma membrane of human lung alveolar type II cells

Type 2 alveolar cells are stem cells in adult lung

Regeneration of the lung alveolus by an evolutionarily conserved epithelial 21 progenitor

Long-term expansion of alveolar stem cells derived from human iPS cells in 23 organoids

Emergence of Drift Variants That

Affect COVID-19 Vaccine Development and Antibody Treatment

Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized 27 mice and is a promising target for new drug development

Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-30

Expression of SARS-CoV-32 2 entry factors in lung epithelial stem cells and its potential implications for COVID-19

Tissue distribution of ACE2 protein, the functional receptor for SARS 35 coronavirus. A first step in understanding SARS pathogenesis

Generation of multipotent lung and airway progenitors from mouse ESCs and 37 patient-specific cystic fibrosis iPSCs

Efficient generation of lung and airway epithelial cells from human pluripotent 39 stem cells

Perfusion decellularization of human and porcine lungs: bringing the matrix to 2 clinical scale

Regeneration and orthotopic transplantation of a bioartificial lung

Isolation and culture of human alveolar epithelial progenitor cells

Development of the lung

☐ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☒ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Harald C Ott reports financial support was provided by United Therapeutics Corp. H.C.O. is founder and stockholder of IVIVA Medical, Inc. This relationship did not affect the content or conclusions contained in this manuscript. Others declare no competing interests.